CD33 and acute myeloid leukemia: Finally, we could independently validate the reduced killing of TP53-deficient isogenic cells in a CRISPR/Cas9-engineered TP53 isogenic MV4-11 AML cell line with TP53 wild-type or knockout alleles co-incubated with CAR T-cells targeting either CD33 or CD123, and across several log2 fold E:T ratios.